

NOVACYT ORDINARY SHAREHOLDERS' MEETING

Shareholders approved all the ordinary resolutions proposed by the Board of Directors

Paris, France and Cambridge, UK – 12 JULY 2016, – Novacyt (ALTERNEXT: ALNOV), an international specialist in cancer and infectious disease diagnostics, announces that at the Company's Annual General Meeting held on 28 June in Paris with a quorum of 47.75%, Novacyt's shareholders adopted either unanimously or by a large majority all ordinary resolutions submitted for their vote by the Board.

The shareholders approved:

- The annual and consolidated accounts for the year 2015;
- The allocation of income of the consolidated annual accounts for the year 2015;
- The allocation of the profit for the year 2015;
- Approval of the agreements referred to in Article L. 225/86 of the Commercial Code;
- The Discharge of the Board of Directors;
- Authorization for the Company to repurchase its own shares;
- Determination of attendance fees allocated to members of the Board;
- Authority with respect to formalities.

Upcoming financial events:

- Revenues for the first half 2016: 21 July 2016
- Half Year Results 2016: 27 October 2016

Disclaimer

This press release does not constitute or should not be considered as a public offering, an offer to subscribe to the company's securities or a public solicitation in preparation of a public offering of Novacyt's securities. No public offering of Novacyt's securities will be made, inside or outside of France, pursuant to Article L. 411-2 of the French Monetary and Financial Code. Consequently, no Prospectus will be published nor approved by the AMF.

- End -

About Novacyt Group

The Novacyt Group is a leader in the field of cellular diagnostics with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform NOVAPREP® and a strong international network Novacyt is able to provide an extensive range of oncology and infectious disease diagnostic products. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its global customers and partners include major corporates.

For more information please refer to the website: www.novacyt.com

Contacts:

International

Brett Pollard / Victoria Foster Mitchell

FTI Consulting

+44 (0)20 3727 1000

brett.pollard@fticonsulting.com / victoria.fostermitchell@fticonsulting.com

France

Arnaud de Cheffontaines / Astrid Villette

FTI Consulting

+33 (0)147 03 69 47 / +33 (0)147 03 69 51

arnaud.decheffontaines@fticonsulting.com / astrid.villette@fticonsulting.com

NOVACYT

Graham Mullis

Chief Executive Officer

+44 (0)7901 514 121

graham.mullis@novacyt.com